A comprehensive insight from molecular docking and dynamics with clinical investigation on the impact of direct oral anticoagulants on atheroprotective protein in atrial fibrillation.

ABSTRACT:

Background

Direct oral anticoagulants (DOACs) have high potency against their therapeutic target and are widely used in the treatment of atrial fibrillation (AF). Most DOACs are often claimed to have adverse effects due to off-target inhibition of essential proteins. Human serum paraoxonase 1 (PON1), one of the essential proteins, known for its anti-inflammatory and antioxidant properties, could be affected by DOACs. Thus, a comparative evaluation of DOACs and their effect on PON1 protein will aid in recommending the most effective DOACs for AF treatment. This study aimed to assess the impact of DOACs on PON1 through a combination of computational and experimental analyses.

Methods

We focus on apixaban, dabigatran, and rivaroxaban, the most recommended DOACs in AF treatment,

SUBMITTER: Sudhan M 

PROVIDER: S-EPMC11342603 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature